You heard correctly.
Fingerprints are required to cash checks at the bank.
Fingerprints are used to access mobile phones.
Cars are next. Not just to open the door, but to start the engine.
"This technology will be used in cars in two to four years," said Godfrey Cheng, corporate vice president for Silicon Valley-based Synaptics. "Driver identification will be revolutionary."
Understanding that car fobs present an increasing security risk, auto companies are following the lead of personal technology devices and moving toward vehicle access through fingerprinting, facial recognition and retina scans.
Top Bank Stocks To Invest In Right Now: Xenon Pharmaceuticals Inc.(XENE)
Advisors' Opinion:- [By Chris Lange]
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares saw a handy gain on Tuesday after the firm announced positive data from a couple of its trials. Specifically, Xenon presented data from its XEN901 Phase 1 clinical trial and from its XEN1101 Phase 1 clinical trial at the Eilat Conference on New Antiepileptic Drugs and Devices in Madrid, Spain.
- [By Joseph Griffin]
Xenon Pharmaceuticals Inc (NASDAQ:XENE) hit a new 52-week high and low during trading on Tuesday . The company traded as low as $8.30 and last traded at $8.25, with a volume of 4819 shares. The stock had previously closed at $7.10.
- [By Ethan Ryder]
Xenon Pharmaceuticals Inc (NASDAQ:XENE) traded up 2.7% during mid-day trading on Monday . The stock traded as high as $11.00 and last traded at $9.60. 1,488 shares changed hands during trading, a decline of 100% from the average session volume of 400,794 shares. The stock had previously closed at $9.35.
- [By Shane Hupp]
Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top Bank Stocks To Invest In Right Now: Zogenix, Inc.(ZGNX)
Advisors' Opinion:- [By Logan Wallace]
Stock analysts at B. Riley assumed coverage on shares of Zogenix (NASDAQ:ZGNX) in a research note issued on Friday. The firm set a “buy” rating and a $116.00 price target on the stock. B. Riley’s price objective points to a potential upside of 154.11% from the stock’s current price.
- [By Maxx Chatsko]
Shares of Zogenix (NASDAQ:ZGNX) fell nearly 15% last month, according to data provided by S&P Global Market Intelligence. The pharma company announced it was issuing up to 6.9 million shares of common stock at $52 apiece. While Mr. Market wasn't thrilled with the dilution, the share offering was actually a pretty wise move. That's because it took advantage of a recent surge in the stock price to raise up to $359 million in gross proceeds.
- [By Shane Hupp]
Get a free copy of the Zacks research report on Zogenix (ZGNX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Cory Renauer]
Here's what you need to know about the catalysts that could send these stocks soaring, or plummeting, in the third quarter.
Company Market Cap Incoming Catalyst Spark Therapeutics Inc. (NASDAQ:ONCE) $3.09 billion Clinical trial results Zogenix, Inc. (NASDAQ:ZGNX) $1.56 billion Clinical trial results Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) $593 million PDUFA dateData source: Yahoo! Finance.
- [By Max Byerly]
Zogenix (NASDAQ:ZGNX) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Friday.
- [By Todd Campbell]
After securing Food and Drug Administration (FDA) and Drug Enforcement Agency (DEA) OKs, GW Pharmaceuticals (NASDAQ:GWPH) plans to launch its marijuana-derived epilepsy medication, Epidiolex, in six weeks. There's a huge unmet need for new treatment options for epilepsy patients who fail to respond to anti-epileptic medications, so optimism is high that Epidiolex could be a top seller. The drug's commercial success, however, could depend on whether regulators approve a rival drug from Zogenix (NASDAQ:ZGNX).
Top Bank Stocks To Invest In Right Now: RealD Inc(RLD)
Advisors' Opinion:- [By Shane Hupp]
News coverage about RealD (NYSE:RLD) has been trending somewhat negative on Thursday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. RealD earned a news impact score of -0.11 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.1473505020268 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
No comments:
Post a Comment